Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) shares soared 23.80 percent to close at $8.27 a share Wednesday. The stock traded between $6.64 and $9.39 on volume of 16.12 million shares traded. Japan's Nikkei newspaper has reported that Otsuka Holdings will purchase Astex Pharmaceuticals for approximately $900.0 million. Shares of Astex Pharmaceuticals have gained approximately 180.0 percent year-to-date.
Get more information on Astex Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ASTX
C.R. Bard, Inc. (NYSE: BCR) shares increased 1.81 percent to close at $116.73 share Wednesday. The stock traded between $113.65 and $116.77 on volume of 536,854 shares traded. The company announced it has agreed to acquire Rochester Medical, Inc. for approximately $262.0 million. Shares of C.R. Bard have gained approximately 19.0 percent year-to-date.
Get more information on C.R. Bard and free access to the in-depth equity report at:
www.FiveStarEquities.com/BCR
Himax Technologies, Inc. (NASDAQ: HIMX) shares spiked 13.43 percent to close at $7.35 a share Wednesday. The stock traded between $6.64 and $7.58 on volume of 28.09 million shares traded. The company recently announced that it will attend the Credit Suisse Asian Technology and the Oppenheimer Emerging Innovations Conferences in September. Shares of Himax Technologies have gained over 200.0 percent year-to-date.
Get more information on Himax Technologies and free access to the in-depth equity report at:
www.FiveStarEquities.com/HIMX
MiMedx Group Inc. (NASDAQ: MDXG) shares plunged 36.47 percent to close at $3.85 a share Wednesday. The stock traded between $1.81 and $6.21 on volume of 4.80 million shares traded. The company announced it has received an "Untitled Letter" from the FDA.
Get more information on MiMedx Group and free access to the in-depth equity report at:
www.FiveStarEquities.com/MDXG
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com